Spyre Therapeutics CFO Scott Burrows sells $2.26m in stock

Scott L. Burrows, Chief Financial Officer of Spyre Therapeutics, Inc. (NASDAQ:SYRE), reported significant stock transactions in a recent SEC Form 4 filing. Burrows sold a total of 25,000 shares of common stock for approximately $2.26 million across September 30 and October 1, 2026. These sales followed the exercise of stock options to acquire an equivalent number of shares. The timing is notable as Spyre’s stock has surged 486% over the past year, though InvestingPro analysis suggests the stock is currently overvalued relative to its Fair Value, placing it among the most overvalued stocks in the market.

On September 30, 2026, Burrows disposed of 17,500 shares at a weighted average price of $89.89 per share. These shares were sold in multiple transactions with prices ranging from $89.00 to $90.62. This transaction totaled approximately $1,573,075.

The following day, October 1, 2026, Burrows sold an additional 7,500 shares, executed under a Rule 10b5-1 trading plan adopted on November 10, 2025. These sales, totaling approximately $688,755, occurred at weighted average prices ranging from $89.07 to $93.57. Specifically, the October 1 sales included:

600 shares at a weighted average price of $89.07, with prices ranging from $88.63 to $89.53.

1,500 shares at a weighted average price of $90.27, with prices ranging from $89.96 to $90.95.

2,100 shares at a weighted average price of $91.92, with prices ranging from $91.41 to $92.26.

3,071 shares at a weighted average price of $92.95, with prices ranging from $92.54 to $93.53.

229 shares at a weighted average price of $93.57, with prices ranging from $93.54 to $93.59.

Concurrently with the sales, Burrows exercised stock options to acquire 17,500 shares of common stock on September 30, 2026, at an exercise price of $14.50 per share, totaling $253,750. On October 1, 2026, he exercised additional options for 7,500 shares at the same exercise price of $14.50 per share, totaling $108,750. These options are part of a larger grant, adjusted for a 1-for-25 reverse stock split on September 8, 2023, with vesting schedules tied to continued employment.

Following these transactions, Scott L. Burrows directly holds 79,762 shares of Spyre Therapeutics common stock. This total includes 33,738 Restricted Stock Units (RSUs) that represent a contingent right to receive shares upon vesting on September 1, 2027, subject to continued employment. He also holds 312,357 derivative securities (stock options) after the reported exercises. InvestingPro Tips highlight that the stock exhibits highly volatile price movements with a beta of 3, which investors should consider when evaluating these insider transactions. Subscribers have access to 10 additional ProTips for deeper analysis.

In other recent news, Spyre Therapeutics has announced important developments regarding its clinical trials and received several analyst ratings. The company reported topline results from its Phase II SKYWAY-RA program, where SPY072/TL1A showed statistically significant improvements over placebo in rheumatoid arthritis patients, though the effect size did not meet Spyre’s internal threshold for monotherapy prioritization. Despite this, Guggenheim reiterated a Buy rating with a $130 price target, citing the program’s evidence of target engagement. Stifel also maintained a Buy rating with a $123 price target after noting the study achieved statistical significance on some endpoints but lacked a competitive effect size for monotherapy.

In addition, Baird reiterated an Outperform rating with a $116 price target, highlighting positive trial data from the SPY003 study in ulcerative colitis. JPMorgan initiated coverage of Spyre with an Overweight rating and a $110 price target, pointing to the company’s competitive pipeline for inflammatory bowel disease. These developments reflect the company’s ongoing efforts in clinical trials and the mixed responses from analysts regarding its recent results.